Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06057051 · ClinicalTrials.gov registry record · NA
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
A NA study of Glaucoma, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 245
- Enrollment target
- 1
- Study location
NCT06057051: Recruiting NA study of Glaucoma, sponsored by Glaukos Corporation.
NCT06057051 is a NA study of Glaucoma that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 245 participants, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06057051, a NA study of Glaucoma, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 245 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
Conditions Studied
Interventions
- DEVICE iStent Infinite
Study Locations (1)
Ohio
- Glaukos Investigator Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2027-08 |
| Phase | NA |
What NCT06057051 shows while recruiting
NCT06057051 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 908-participant average among 92 other Glaucoma trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which iStent Infinite is the first listed.
NCT06057051 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06057051 about?
NCT06057051 is a clinical study titled "Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma". Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
What is the current status of trial NCT06057051?
This trial is currently recruiting. It is a NA study. The enrollment target is 245 participants. The study started on 2023-09-01. Estimated completion is 2027-08.
What conditions does trial NCT06057051 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT06057051?
The interventions under investigation include: iStent Infinite (DEVICE).
Who is sponsoring clinical trial NCT06057051?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06057051 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06057051's enrollment target sits among peer trials
245 21st of 92 higher than 72 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Glaucoma
RECRUITING · NA
-
Hyperbaric Oxygen Therapy for Optic Neuropathies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI